Refocus, Optimize, Externalize: Takeda Overhauls Global R&D

Under a sweeping new blueprint to refocus, optimize, and externalize its worldwide R&D activities, Takeda Pharmaceutical Co. Ltd. is to simplify its current network of internal sites, transfer an as yet unspecified but "significant" number of employees to new external partners, and fundamentally transform ways of working as it pursues improved focus, efficiency and appropriate capability in its operations.

As has already been indicated by the Japanese firm, it will reduce and concentrate its R&D presence on three core therapeutic growth areas - oncology, gastroenterology, and CNS, plus vaccines...